nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—SLCO1B1—Rifampicin—leprosy	0.153	0.2	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Rifampicin—leprosy	0.0898	0.117	CbGbCtD
Sirolimus—CYP3A7—Rifampicin—leprosy	0.0898	0.117	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Dapsone—leprosy	0.0742	0.0969	CbGbCtD
Sirolimus—CYP3A7—Dapsone—leprosy	0.0742	0.0969	CbGbCtD
Sirolimus—CYP3A5—Thalidomide—leprosy	0.0696	0.0909	CbGbCtD
Sirolimus—CYP3A5—Rifampicin—leprosy	0.0674	0.088	CbGbCtD
Sirolimus—CYP3A5—Dapsone—leprosy	0.0556	0.0727	CbGbCtD
Sirolimus—ABCB1—Rifampicin—leprosy	0.0439	0.0573	CbGbCtD
Sirolimus—CYP3A4—Rifampicin—leprosy	0.0263	0.0343	CbGbCtD
Sirolimus—CYP3A4—Dapsone—leprosy	0.0217	0.0283	CbGbCtD
Sirolimus—Hormone level abnormal—Thalidomide—leprosy	0.00963	0.0547	CcSEcCtD
Sirolimus—Pneumocystis jirovecii pneumonia—Thalidomide—leprosy	0.00724	0.0411	CcSEcCtD
Sirolimus—MTOR—hindlimb—leprosy	0.00691	0.156	CbGeAlD
Sirolimus—Benign neoplasm of skin—Thalidomide—leprosy	0.00671	0.0381	CcSEcCtD
Sirolimus—MTOR—appendage—leprosy	0.00593	0.134	CbGeAlD
Sirolimus—Lymphoedema—Thalidomide—leprosy	0.00372	0.0211	CcSEcCtD
Sirolimus—Nephrotic syndrome—Dapsone—leprosy	0.00367	0.0208	CcSEcCtD
Sirolimus—Peritonitis—Thalidomide—leprosy	0.0036	0.0204	CcSEcCtD
Sirolimus—MTOR—blood vessel—leprosy	0.0033	0.0744	CbGeAlD
Sirolimus—Hypoproteinaemia—Thalidomide—leprosy	0.00309	0.0176	CcSEcCtD
Sirolimus—Circumoral paresthesia—Thalidomide—leprosy	0.00279	0.0158	CcSEcCtD
Sirolimus—FGF2—eye—leprosy	0.00277	0.0624	CbGeAlD
Sirolimus—Pyuria—Thalidomide—leprosy	0.0026	0.0148	CcSEcCtD
Sirolimus—EIF4E—testis—leprosy	0.00249	0.0561	CbGeAlD
Sirolimus—EIF4E—nervous system—leprosy	0.00244	0.0551	CbGeAlD
Sirolimus—Albuminuria—Dapsone—leprosy	0.00238	0.0135	CcSEcCtD
Sirolimus—Fungal skin infection—Thalidomide—leprosy	0.00217	0.0123	CcSEcCtD
Sirolimus—Proteinuria—Dapsone—leprosy	0.00202	0.0115	CcSEcCtD
Sirolimus—Ascites—Thalidomide—leprosy	0.002	0.0114	CcSEcCtD
Sirolimus—Protein urine present—Dapsone—leprosy	0.00199	0.0113	CcSEcCtD
Sirolimus—Hernia—Thalidomide—leprosy	0.00194	0.011	CcSEcCtD
Sirolimus—Paraesthesia oral—Thalidomide—leprosy	0.00194	0.011	CcSEcCtD
Sirolimus—Peripheral vascular disorder—Thalidomide—leprosy	0.00185	0.0105	CcSEcCtD
Sirolimus—FGF2—tendon—leprosy	0.00183	0.0413	CbGeAlD
Sirolimus—Embolism venous—Thalidomide—leprosy	0.0018	0.0102	CcSEcCtD
Sirolimus—Lactic dehydrogenase activity increased—Thalidomide—leprosy	0.00177	0.0101	CcSEcCtD
Sirolimus—MTOR—eye—leprosy	0.00176	0.0396	CbGeAlD
Sirolimus—FKBP1A—eye—leprosy	0.00158	0.0356	CbGeAlD
Sirolimus—Blood lactate dehydrogenase increased—Thalidomide—leprosy	0.00156	0.00888	CcSEcCtD
Sirolimus—MTOR—skin of body—leprosy	0.00153	0.0345	CbGeAlD
Sirolimus—FGF2—testis—leprosy	0.00152	0.0342	CbGeAlD
Sirolimus—Enlargement abdomen—Thalidomide—leprosy	0.00151	0.00857	CcSEcCtD
Sirolimus—Deep vein thrombosis—Thalidomide—leprosy	0.00149	0.00848	CcSEcCtD
Sirolimus—Hypomagnesaemia—Thalidomide—leprosy	0.00143	0.00812	CcSEcCtD
Sirolimus—Oral candidiasis—Thalidomide—leprosy	0.00143	0.00812	CcSEcCtD
Sirolimus—Nail disorder—Thalidomide—leprosy	0.0014	0.00795	CcSEcCtD
Sirolimus—FKBP1A—skin of body—leprosy	0.00137	0.031	CbGeAlD
Sirolimus—SLC47A1—eye—leprosy	0.00136	0.0306	CbGeAlD
Sirolimus—Menstrual disorder—Thalidomide—leprosy	0.00133	0.00757	CcSEcCtD
Sirolimus—Hypercalcaemia—Thalidomide—leprosy	0.00131	0.00742	CcSEcCtD
Sirolimus—Thrombosis—Thalidomide—leprosy	0.00128	0.00729	CcSEcCtD
Sirolimus—Interstitial lung disease—Thalidomide—leprosy	0.00128	0.00729	CcSEcCtD
Sirolimus—Metrorrhagia—Thalidomide—leprosy	0.00127	0.00722	CcSEcCtD
Sirolimus—Hyperlipidaemia—Thalidomide—leprosy	0.00126	0.00716	CcSEcCtD
Sirolimus—Albuminuria—Thalidomide—leprosy	0.00122	0.00691	CcSEcCtD
Sirolimus—Pleural effusion—Thalidomide—leprosy	0.00119	0.00674	CcSEcCtD
Sirolimus—Skin ulcer—Thalidomide—leprosy	0.00117	0.00663	CcSEcCtD
Sirolimus—MTOR—tendon—leprosy	0.00116	0.0262	CbGeAlD
Sirolimus—FKBP1A—Alpha-synuclein signaling—PARK2—leprosy	0.00114	0.0822	CbGpPWpGaD
Sirolimus—Influenza—Dapsone—leprosy	0.00111	0.00632	CcSEcCtD
Sirolimus—Pancreatitis—Dapsone—leprosy	0.00109	0.0062	CcSEcCtD
Sirolimus—Acne—Thalidomide—leprosy	0.00108	0.00613	CcSEcCtD
Sirolimus—FKBP1A—tendon—leprosy	0.00105	0.0236	CbGeAlD
Sirolimus—Amenorrhoea—Thalidomide—leprosy	0.00103	0.00587	CcSEcCtD
Sirolimus—Proteinuria—Thalidomide—leprosy	0.00103	0.00587	CcSEcCtD
Sirolimus—Accidental injury—Thalidomide—leprosy	0.00103	0.00583	CcSEcCtD
Sirolimus—Protein urine present—Thalidomide—leprosy	0.00102	0.00579	CcSEcCtD
Sirolimus—Viral infection—Thalidomide—leprosy	0.00101	0.00571	CcSEcCtD
Sirolimus—Bone disorder—Thalidomide—leprosy	0.00101	0.00571	CcSEcCtD
Sirolimus—Arthropathy—Thalidomide—leprosy	0.000999	0.00567	CcSEcCtD
Sirolimus—Cellulitis—Thalidomide—leprosy	0.000999	0.00567	CcSEcCtD
Sirolimus—Hyperbilirubinaemia—Thalidomide—leprosy	0.000999	0.00567	CcSEcCtD
Sirolimus—Hypocalcaemia—Thalidomide—leprosy	0.000992	0.00563	CcSEcCtD
Sirolimus—Oliguria—Thalidomide—leprosy	0.000986	0.0056	CcSEcCtD
Sirolimus—Herpes simplex—Thalidomide—leprosy	0.000986	0.0056	CcSEcCtD
Sirolimus—Hyperuricaemia—Thalidomide—leprosy	0.000979	0.00556	CcSEcCtD
Sirolimus—Neuropathy peripheral—Dapsone—leprosy	0.000973	0.00553	CcSEcCtD
Sirolimus—Leukocytosis—Thalidomide—leprosy	0.000966	0.00549	CcSEcCtD
Sirolimus—MTOR—testis—leprosy	0.000964	0.0217	CbGeAlD
Sirolimus—Hypercholesterolaemia—Thalidomide—leprosy	0.00096	0.00545	CcSEcCtD
Sirolimus—Creatinine increased—Thalidomide—leprosy	0.000954	0.00542	CcSEcCtD
Sirolimus—Bone pain—Thalidomide—leprosy	0.000948	0.00538	CcSEcCtD
Sirolimus—MTOR—nervous system—leprosy	0.000946	0.0213	CbGeAlD
Sirolimus—Sinusitis—Dapsone—leprosy	0.000931	0.00529	CcSEcCtD
Sirolimus—Blood uric acid increased—Thalidomide—leprosy	0.000925	0.00525	CcSEcCtD
Sirolimus—Pulmonary embolism—Thalidomide—leprosy	0.000908	0.00516	CcSEcCtD
Sirolimus—Hepatocellular injury—Thalidomide—leprosy	0.000908	0.00516	CcSEcCtD
Sirolimus—Phosphatase alkaline increased—Thalidomide—leprosy	0.000908	0.00516	CcSEcCtD
Sirolimus—SLC47A1—tendon—leprosy	0.0009	0.0203	CbGeAlD
Sirolimus—Eructation—Thalidomide—leprosy	0.000892	0.00507	CcSEcCtD
Sirolimus—Hyperkalaemia—Thalidomide—leprosy	0.000892	0.00507	CcSEcCtD
Sirolimus—Pharyngitis—Dapsone—leprosy	0.000884	0.00502	CcSEcCtD
Sirolimus—Candida infection—Thalidomide—leprosy	0.000867	0.00492	CcSEcCtD
Sirolimus—FKBP1A—testis—leprosy	0.000867	0.0195	CbGeAlD
Sirolimus—Blood urea increased—Thalidomide—leprosy	0.000857	0.00487	CcSEcCtD
Sirolimus—Neuropathy—Thalidomide—leprosy	0.000853	0.00484	CcSEcCtD
Sirolimus—FKBP1A—nervous system—leprosy	0.000851	0.0192	CbGeAlD
Sirolimus—Cramps of lower extremities—Thalidomide—leprosy	0.000834	0.00474	CcSEcCtD
Sirolimus—Tinnitus—Dapsone—leprosy	0.000831	0.00472	CcSEcCtD
Sirolimus—Oesophagitis—Thalidomide—leprosy	0.00083	0.00471	CcSEcCtD
Sirolimus—Pulmonary oedema—Thalidomide—leprosy	0.000808	0.00459	CcSEcCtD
Sirolimus—Hypertonia—Thalidomide—leprosy	0.000796	0.00452	CcSEcCtD
Sirolimus—Sepsis—Thalidomide—leprosy	0.000788	0.00448	CcSEcCtD
Sirolimus—Lymphadenopathy—Thalidomide—leprosy	0.000773	0.00439	CcSEcCtD
Sirolimus—Thrombophlebitis—Thalidomide—leprosy	0.000762	0.00433	CcSEcCtD
Sirolimus—Blood alkaline phosphatase increased—Thalidomide—leprosy	0.000758	0.0043	CcSEcCtD
Sirolimus—Diabetes mellitus—Thalidomide—leprosy	0.000758	0.0043	CcSEcCtD
Sirolimus—SLC47A1—testis—leprosy	0.000745	0.0168	CbGeAlD
Sirolimus—Gastroenteritis—Thalidomide—leprosy	0.000744	0.00422	CcSEcCtD
Sirolimus—Deafness—Thalidomide—leprosy	0.000737	0.00419	CcSEcCtD
Sirolimus—SLC47A1—nervous system—leprosy	0.000731	0.0165	CbGeAlD
Sirolimus—Cardiac failure congestive—Thalidomide—leprosy	0.000727	0.00413	CcSEcCtD
Sirolimus—EIF4E—Hypertrophy Model—IFNG—leprosy	0.000726	0.0523	CbGpPWpGaD
Sirolimus—Injury—Thalidomide—leprosy	0.000717	0.00407	CcSEcCtD
Sirolimus—Increased appetite—Thalidomide—leprosy	0.000702	0.00399	CcSEcCtD
Sirolimus—Dermatitis exfoliative—Thalidomide—leprosy	0.000699	0.00397	CcSEcCtD
Sirolimus—Atrial fibrillation—Thalidomide—leprosy	0.000696	0.00395	CcSEcCtD
Sirolimus—ABCB1—blood vessel—leprosy	0.000687	0.0155	CbGeAlD
Sirolimus—Cough—Dapsone—leprosy	0.000677	0.00384	CcSEcCtD
Sirolimus—Hypoglycaemia—Thalidomide—leprosy	0.000676	0.00384	CcSEcCtD
Sirolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CD40LG—leprosy	0.000673	0.0484	CbGpPWpGaD
Sirolimus—Hyponatraemia—Thalidomide—leprosy	0.000662	0.00376	CcSEcCtD
Sirolimus—Osteoarthritis—Thalidomide—leprosy	0.000659	0.00374	CcSEcCtD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—TNFSF15—leprosy	0.000659	0.0475	CbGpPWpGaD
Sirolimus—Affect lability—Thalidomide—leprosy	0.000649	0.00369	CcSEcCtD
Sirolimus—Face oedema—Thalidomide—leprosy	0.000637	0.00361	CcSEcCtD
Sirolimus—Mood swings—Thalidomide—leprosy	0.000625	0.00355	CcSEcCtD
Sirolimus—SLC47A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—leprosy	0.00062	0.0446	CbGpPWpGaD
Sirolimus—Tachycardia—Dapsone—leprosy	0.000618	0.00351	CcSEcCtD
Sirolimus—Blood creatinine increased—Thalidomide—leprosy	0.000618	0.00351	CcSEcCtD
Sirolimus—Dehydration—Thalidomide—leprosy	0.000613	0.00348	CcSEcCtD
Sirolimus—Liver function test abnormal—Thalidomide—leprosy	0.000609	0.00346	CcSEcCtD
Sirolimus—Orthostatic hypotension—Thalidomide—leprosy	0.000602	0.00342	CcSEcCtD
Sirolimus—Hypokalaemia—Thalidomide—leprosy	0.0006	0.00341	CcSEcCtD
Sirolimus—Breast disorder—Thalidomide—leprosy	0.000596	0.00338	CcSEcCtD
Sirolimus—Aspartate aminotransferase increased—Thalidomide—leprosy	0.000594	0.00337	CcSEcCtD
Sirolimus—MTOR—IL4-mediated signaling events—LTA—leprosy	0.000592	0.0426	CbGpPWpGaD
Sirolimus—Alanine aminotransferase increased—Thalidomide—leprosy	0.000582	0.0033	CcSEcCtD
Sirolimus—Abdominal distension—Thalidomide—leprosy	0.000574	0.00326	CcSEcCtD
Sirolimus—Insomnia—Dapsone—leprosy	0.000573	0.00325	CcSEcCtD
Sirolimus—Dysphagia—Thalidomide—leprosy	0.00057	0.00324	CcSEcCtD
Sirolimus—Influenza—Thalidomide—leprosy	0.00057	0.00324	CcSEcCtD
Sirolimus—Pancreatitis—Thalidomide—leprosy	0.000559	0.00317	CcSEcCtD
Sirolimus—Bronchitis—Thalidomide—leprosy	0.000548	0.00311	CcSEcCtD
Sirolimus—Pancytopenia—Thalidomide—leprosy	0.000541	0.00307	CcSEcCtD
Sirolimus—Neutropenia—Thalidomide—leprosy	0.000533	0.00303	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Thalidomide—leprosy	0.00053	0.00301	CcSEcCtD
Sirolimus—Pollakiuria—Thalidomide—leprosy	0.000526	0.00299	CcSEcCtD
Sirolimus—Erectile dysfunction—Thalidomide—leprosy	0.000525	0.00298	CcSEcCtD
Sirolimus—Weight increased—Thalidomide—leprosy	0.000519	0.00295	CcSEcCtD
Sirolimus—Gastrointestinal pain—Dapsone—leprosy	0.000518	0.00294	CcSEcCtD
Sirolimus—Weight decreased—Thalidomide—leprosy	0.000516	0.00293	CcSEcCtD
Sirolimus—Hyperglycaemia—Thalidomide—leprosy	0.000514	0.00292	CcSEcCtD
Sirolimus—Pneumonia—Thalidomide—leprosy	0.000511	0.0029	CcSEcCtD
Sirolimus—Infestation NOS—Thalidomide—leprosy	0.000508	0.00289	CcSEcCtD
Sirolimus—Infestation—Thalidomide—leprosy	0.000508	0.00289	CcSEcCtD
Sirolimus—Abdominal pain—Dapsone—leprosy	0.0005	0.00284	CcSEcCtD
Sirolimus—Body temperature increased—Dapsone—leprosy	0.0005	0.00284	CcSEcCtD
Sirolimus—Neuropathy peripheral—Thalidomide—leprosy	0.000498	0.00283	CcSEcCtD
Sirolimus—Stomatitis—Thalidomide—leprosy	0.000495	0.00281	CcSEcCtD
Sirolimus—Conjunctivitis—Thalidomide—leprosy	0.000494	0.0028	CcSEcCtD
Sirolimus—Sweating—Thalidomide—leprosy	0.000487	0.00277	CcSEcCtD
Sirolimus—Haematuria—Thalidomide—leprosy	0.000484	0.00275	CcSEcCtD
Sirolimus—Epistaxis—Thalidomide—leprosy	0.000479	0.00272	CcSEcCtD
Sirolimus—Sinusitis—Thalidomide—leprosy	0.000477	0.00271	CcSEcCtD
Sirolimus—Rhinitis—Thalidomide—leprosy	0.000457	0.0026	CcSEcCtD
Sirolimus—Hypoaesthesia—Thalidomide—leprosy	0.000454	0.00258	CcSEcCtD
Sirolimus—Pharyngitis—Thalidomide—leprosy	0.000453	0.00257	CcSEcCtD
Sirolimus—Urinary tract disorder—Thalidomide—leprosy	0.00045	0.00256	CcSEcCtD
Sirolimus—Oedema peripheral—Thalidomide—leprosy	0.000449	0.00255	CcSEcCtD
Sirolimus—Urethral disorder—Thalidomide—leprosy	0.000447	0.00254	CcSEcCtD
Sirolimus—Visual impairment—Thalidomide—leprosy	0.00044	0.0025	CcSEcCtD
Sirolimus—Tinnitus—Thalidomide—leprosy	0.000425	0.00242	CcSEcCtD
Sirolimus—Cardiac disorder—Thalidomide—leprosy	0.000423	0.0024	CcSEcCtD
Sirolimus—Angiopathy—Thalidomide—leprosy	0.000414	0.00235	CcSEcCtD
Sirolimus—Immune system disorder—Thalidomide—leprosy	0.000412	0.00234	CcSEcCtD
Sirolimus—Mediastinal disorder—Thalidomide—leprosy	0.000411	0.00233	CcSEcCtD
Sirolimus—Chills—Thalidomide—leprosy	0.000409	0.00232	CcSEcCtD
Sirolimus—Vomiting—Dapsone—leprosy	0.000402	0.00229	CcSEcCtD
Sirolimus—Malnutrition—Thalidomide—leprosy	0.000397	0.00225	CcSEcCtD
Sirolimus—Headache—Dapsone—leprosy	0.000397	0.00225	CcSEcCtD
Sirolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IFNG—leprosy	0.000396	0.0285	CbGpPWpGaD
Sirolimus—Flatulence—Thalidomide—leprosy	0.000391	0.00222	CcSEcCtD
Sirolimus—Tension—Thalidomide—leprosy	0.00039	0.00221	CcSEcCtD
Sirolimus—Nervousness—Thalidomide—leprosy	0.000386	0.00219	CcSEcCtD
Sirolimus—Back pain—Thalidomide—leprosy	0.000384	0.00218	CcSEcCtD
Sirolimus—Muscle spasms—Thalidomide—leprosy	0.000382	0.00217	CcSEcCtD
Sirolimus—Nausea—Dapsone—leprosy	0.000376	0.00214	CcSEcCtD
Sirolimus—Tremor—Thalidomide—leprosy	0.000372	0.00211	CcSEcCtD
Sirolimus—Ill-defined disorder—Thalidomide—leprosy	0.000368	0.00209	CcSEcCtD
Sirolimus—Anaemia—Thalidomide—leprosy	0.000367	0.00208	CcSEcCtD
Sirolimus—Agitation—Thalidomide—leprosy	0.000365	0.00207	CcSEcCtD
Sirolimus—Angioedema—Thalidomide—leprosy	0.000363	0.00206	CcSEcCtD
Sirolimus—Malaise—Thalidomide—leprosy	0.000358	0.00203	CcSEcCtD
Sirolimus—Syncope—Thalidomide—leprosy	0.000356	0.00202	CcSEcCtD
Sirolimus—Leukopenia—Thalidomide—leprosy	0.000355	0.00202	CcSEcCtD
Sirolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL2—leprosy	0.000351	0.0253	CbGpPWpGaD
Sirolimus—Palpitations—Thalidomide—leprosy	0.000351	0.00199	CcSEcCtD
Sirolimus—Loss of consciousness—Thalidomide—leprosy	0.000349	0.00198	CcSEcCtD
Sirolimus—Cough—Thalidomide—leprosy	0.000346	0.00197	CcSEcCtD
Sirolimus—Hypertension—Thalidomide—leprosy	0.000343	0.00195	CcSEcCtD
Sirolimus—Arthralgia—Thalidomide—leprosy	0.000338	0.00192	CcSEcCtD
Sirolimus—Chest pain—Thalidomide—leprosy	0.000338	0.00192	CcSEcCtD
Sirolimus—Myalgia—Thalidomide—leprosy	0.000338	0.00192	CcSEcCtD
Sirolimus—Anxiety—Thalidomide—leprosy	0.000337	0.00191	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.000336	0.00191	CcSEcCtD
Sirolimus—Discomfort—Thalidomide—leprosy	0.000334	0.0019	CcSEcCtD
Sirolimus—Confusional state—Thalidomide—leprosy	0.000327	0.00186	CcSEcCtD
Sirolimus—Oedema—Thalidomide—leprosy	0.000324	0.00184	CcSEcCtD
Sirolimus—Infection—Thalidomide—leprosy	0.000322	0.00183	CcSEcCtD
Sirolimus—Shock—Thalidomide—leprosy	0.000319	0.00181	CcSEcCtD
Sirolimus—Nervous system disorder—Thalidomide—leprosy	0.000318	0.0018	CcSEcCtD
Sirolimus—Thrombocytopenia—Thalidomide—leprosy	0.000317	0.0018	CcSEcCtD
Sirolimus—Tachycardia—Thalidomide—leprosy	0.000316	0.0018	CcSEcCtD
Sirolimus—Skin disorder—Thalidomide—leprosy	0.000315	0.00179	CcSEcCtD
Sirolimus—Hyperhidrosis—Thalidomide—leprosy	0.000313	0.00178	CcSEcCtD
Sirolimus—Anorexia—Thalidomide—leprosy	0.000309	0.00175	CcSEcCtD
Sirolimus—Hypotension—Thalidomide—leprosy	0.000303	0.00172	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Thalidomide—leprosy	0.000295	0.00168	CcSEcCtD
Sirolimus—Insomnia—Thalidomide—leprosy	0.000293	0.00166	CcSEcCtD
Sirolimus—Paraesthesia—Thalidomide—leprosy	0.000291	0.00165	CcSEcCtD
Sirolimus—Dyspnoea—Thalidomide—leprosy	0.000289	0.00164	CcSEcCtD
Sirolimus—Somnolence—Thalidomide—leprosy	0.000288	0.00164	CcSEcCtD
Sirolimus—Dyspepsia—Thalidomide—leprosy	0.000285	0.00162	CcSEcCtD
Sirolimus—Decreased appetite—Thalidomide—leprosy	0.000282	0.0016	CcSEcCtD
Sirolimus—SLC47A1—SLC-mediated transmembrane transport—SLC11A1—leprosy	0.000282	0.0203	CbGpPWpGaD
Sirolimus—Gastrointestinal disorder—Thalidomide—leprosy	0.00028	0.00159	CcSEcCtD
Sirolimus—CYP3A4—nervous system—leprosy	0.000278	0.00626	CbGeAlD
Sirolimus—Pain—Thalidomide—leprosy	0.000277	0.00157	CcSEcCtD
Sirolimus—Constipation—Thalidomide—leprosy	0.000277	0.00157	CcSEcCtD
Sirolimus—MTOR—IL12-mediated signaling events—RIPK2—leprosy	0.000276	0.0199	CbGpPWpGaD
Sirolimus—Feeling abnormal—Thalidomide—leprosy	0.000267	0.00152	CcSEcCtD
Sirolimus—Gastrointestinal pain—Thalidomide—leprosy	0.000265	0.0015	CcSEcCtD
Sirolimus—Body temperature increased—Thalidomide—leprosy	0.000256	0.00145	CcSEcCtD
Sirolimus—Abdominal pain—Thalidomide—leprosy	0.000256	0.00145	CcSEcCtD
Sirolimus—FKBP1A—TGF-beta Receptor Signaling—IFNG—leprosy	0.000241	0.0173	CbGpPWpGaD
Sirolimus—Hypersensitivity—Thalidomide—leprosy	0.000239	0.00136	CcSEcCtD
Sirolimus—Asthenia—Thalidomide—leprosy	0.000232	0.00132	CcSEcCtD
Sirolimus—Pruritus—Thalidomide—leprosy	0.000229	0.0013	CcSEcCtD
Sirolimus—Diarrhoea—Thalidomide—leprosy	0.000222	0.00126	CcSEcCtD
Sirolimus—Dizziness—Thalidomide—leprosy	0.000214	0.00122	CcSEcCtD
Sirolimus—MTOR—IL12-mediated signaling events—CD8A—leprosy	0.000209	0.0151	CbGpPWpGaD
Sirolimus—Vomiting—Thalidomide—leprosy	0.000206	0.00117	CcSEcCtD
Sirolimus—MTOR—IL4-mediated signaling events—CD40LG—leprosy	0.000206	0.0148	CbGpPWpGaD
Sirolimus—MTOR—IL4-mediated signaling events—IL10—leprosy	0.000206	0.0148	CbGpPWpGaD
Sirolimus—Rash—Thalidomide—leprosy	0.000204	0.00116	CcSEcCtD
Sirolimus—Dermatitis—Thalidomide—leprosy	0.000204	0.00116	CcSEcCtD
Sirolimus—Headache—Thalidomide—leprosy	0.000203	0.00115	CcSEcCtD
Sirolimus—ABCB1—testis—leprosy	0.0002	0.00452	CbGeAlD
Sirolimus—ABCB1—nervous system—leprosy	0.000197	0.00443	CbGeAlD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—RIPK2—leprosy	0.000195	0.014	CbGpPWpGaD
Sirolimus—Nausea—Thalidomide—leprosy	0.000192	0.00109	CcSEcCtD
Sirolimus—EIF4E—Interferon Signaling—HLA-DRB1—leprosy	0.00018	0.013	CbGpPWpGaD
Sirolimus—MTOR—Type II diabetes mellitus—TNF—leprosy	0.00018	0.0129	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—NOD2—leprosy	0.000177	0.0127	CbGpPWpGaD
Sirolimus—MTOR—IL12-mediated signaling events—HLA-DRB1—leprosy	0.00017	0.0123	CbGpPWpGaD
Sirolimus—MTOR—IL2 signaling events mediated by PI3K—IL2—leprosy	0.000163	0.0117	CbGpPWpGaD
Sirolimus—MTOR—IFN-gamma pathway—IFNG—leprosy	0.000162	0.0117	CbGpPWpGaD
Sirolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—leprosy	0.000156	0.0112	CbGpPWpGaD
Sirolimus—MTOR—Costimulation by the CD28 family—HLA-DRB1—leprosy	0.000154	0.0111	CbGpPWpGaD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—SLC11A1—leprosy	0.000143	0.0103	CbGpPWpGaD
Sirolimus—EIF4E—Interferon Signaling—IFNG—leprosy	0.000132	0.00948	CbGpPWpGaD
Sirolimus—MTOR—CXCR4-mediated signaling events—HLA-DRB1—leprosy	0.00013	0.00937	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—IFNG—leprosy	0.000129	0.00927	CbGpPWpGaD
Sirolimus—FGF2—Angiopoietin receptor Tie2-mediated signaling—TNF—leprosy	0.000125	0.00904	CbGpPWpGaD
Sirolimus—MTOR—IL12-mediated signaling events—IFNG—leprosy	0.000124	0.00895	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—HLA-DRB1—leprosy	0.00012	0.00867	CbGpPWpGaD
Sirolimus—MTOR—IL12-mediated signaling events—CD4—leprosy	0.00012	0.00865	CbGpPWpGaD
Sirolimus—FGF2—Cardiac Hypertrophic Response—TNF—leprosy	0.000116	0.00837	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—IL2—leprosy	0.000114	0.00824	CbGpPWpGaD
Sirolimus—MTOR—Regulation of Telomerase—IFNG—leprosy	0.000113	0.0081	CbGpPWpGaD
Sirolimus—MTOR—IL12-mediated signaling events—IL2—leprosy	0.000111	0.00796	CbGpPWpGaD
Sirolimus—MTOR—Costimulation by the CD28 family—CD4—leprosy	0.000109	0.00782	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—RIPK2—leprosy	0.000107	0.00768	CbGpPWpGaD
Sirolimus—SLCO1B1—SLC-mediated transmembrane transport—SLC11A1—leprosy	0.000101	0.00725	CbGpPWpGaD
Sirolimus—MTOR—Regulation of Telomerase—IL2—leprosy	0.0001	0.0072	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CYLD—leprosy	9.89e-05	0.00712	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CYLD—leprosy	9.44e-05	0.00679	CbGpPWpGaD
Sirolimus—MTOR—CXCR4-mediated signaling events—CD4—leprosy	9.18e-05	0.00661	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—IFNG—leprosy	8.79e-05	0.00633	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—PARK2—leprosy	8.74e-05	0.00629	CbGpPWpGaD
Sirolimus—MTOR—Cardiac Hypertrophic Response—TNF—leprosy	8.63e-05	0.00621	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—TNF—leprosy	8.33e-05	0.006	CbGpPWpGaD
Sirolimus—FGF2—MicroRNAs in cardiomyocyte hypertrophy—TNF—leprosy	8.29e-05	0.00597	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—PARK2—leprosy	8.01e-05	0.00577	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—IFNG—leprosy	7.95e-05	0.00572	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—RIPK2—leprosy	7.91e-05	0.0057	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—IL2—leprosy	7.81e-05	0.00562	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—IL10—leprosy	7.31e-05	0.00526	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—CD40LG—leprosy	7.31e-05	0.00526	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CYLD—leprosy	7e-05	0.00504	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—RIPK2—leprosy	6.37e-05	0.00459	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—TLR2—leprosy	6.37e-05	0.00459	CbGpPWpGaD
Sirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—leprosy	6.15e-05	0.00443	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—TLR2—leprosy	6.08e-05	0.00438	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—RIPK2—leprosy	6.08e-05	0.00438	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—PARK2—leprosy	5.94e-05	0.00428	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—SLC11A1—leprosy	5.92e-05	0.00426	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—HLA-DRB1—leprosy	5.88e-05	0.00424	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—RIPK2—leprosy	5.84e-05	0.0042	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—NOD2—leprosy	5.78e-05	0.00416	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—leprosy	5.67e-05	0.00408	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—NOD2—leprosy	5.51e-05	0.00397	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CYLD—leprosy	5.5e-05	0.00396	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—SLC11A1—leprosy	5.12e-05	0.00369	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CD40LG—leprosy	4.88e-05	0.00352	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PARK2—leprosy	4.86e-05	0.0035	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CD8A—leprosy	4.83e-05	0.00348	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—TLR2—leprosy	4.51e-05	0.00325	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—RIPK2—leprosy	4.51e-05	0.00325	CbGpPWpGaD
Sirolimus—FGF2—Disease—SLC11A1—leprosy	4.49e-05	0.00323	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CD40LG—leprosy	4.47e-05	0.00322	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CD8A—leprosy	4.42e-05	0.00319	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—RIPK2—leprosy	4.33e-05	0.00312	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—IFNG—leprosy	4.3e-05	0.00309	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TNF—leprosy	4.29e-05	0.00309	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—RIPK2—leprosy	4.12e-05	0.00297	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—NOD2—leprosy	4.09e-05	0.00295	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CYLD—leprosy	4.08e-05	0.00294	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—HLA-DRB1—leprosy	3.93e-05	0.00283	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—IL2—leprosy	3.82e-05	0.00275	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PARK2—leprosy	3.6e-05	0.0026	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HLA-DRB1—leprosy	3.6e-05	0.00259	CbGpPWpGaD
Sirolimus—FGF2—Immune System—RIPK2—leprosy	3.54e-05	0.00255	CbGpPWpGaD
Sirolimus—FGF2—Immune System—TLR2—leprosy	3.54e-05	0.00255	CbGpPWpGaD
Sirolimus—MTOR—Disease—SLC11A1—leprosy	3.33e-05	0.0024	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD40LG—leprosy	3.32e-05	0.00239	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD8A—leprosy	3.28e-05	0.00236	CbGpPWpGaD
Sirolimus—FGF2—Immune System—NOD2—leprosy	3.21e-05	0.00231	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—SDHD—leprosy	3.19e-05	0.0023	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—RIPK2—leprosy	3.02e-05	0.00218	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—SDHD—leprosy	2.93e-05	0.00211	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IFNG—leprosy	2.87e-05	0.00207	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—TNF—leprosy	2.78e-05	0.002	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CD4—leprosy	2.77e-05	0.002	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD40LG—leprosy	2.71e-05	0.00195	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD8A—leprosy	2.68e-05	0.00193	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HLA-DRB1—leprosy	2.67e-05	0.00193	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CD4—leprosy	2.65e-05	0.00191	CbGpPWpGaD
Sirolimus—MTOR—Immune System—RIPK2—leprosy	2.63e-05	0.00189	CbGpPWpGaD
Sirolimus—MTOR—Immune System—TLR2—leprosy	2.63e-05	0.00189	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC11A1—leprosy	2.56e-05	0.00184	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL2—leprosy	2.55e-05	0.00184	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CD4—leprosy	2.54e-05	0.00183	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NOD2—leprosy	2.38e-05	0.00172	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—RIPK2—leprosy	2.29e-05	0.00165	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HLA-DRB1—leprosy	2.19e-05	0.00157	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SDHD—leprosy	2.12e-05	0.00152	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD40LG—leprosy	2.01e-05	0.00145	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—TNF—leprosy	2.01e-05	0.00145	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD8A—leprosy	1.99e-05	0.00143	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CD4—leprosy	1.96e-05	0.00141	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD4—leprosy	1.89e-05	0.00136	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CD4—leprosy	1.88e-05	0.00135	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RIPK2—leprosy	1.7e-05	0.00122	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL2—leprosy	1.65e-05	0.00119	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HLA-DRB1—leprosy	1.62e-05	0.00117	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SDHD—leprosy	1.6e-05	0.00115	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IFNG—leprosy	1.6e-05	0.00115	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD4—leprosy	1.54e-05	0.00111	CbGpPWpGaD
Sirolimus—FGF2—Disease—CD4—leprosy	1.42e-05	0.00102	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL2—leprosy	1.42e-05	0.00102	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—leprosy	1.37e-05	0.000988	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL2—leprosy	1.21e-05	0.000871	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IFNG—leprosy	1.18e-05	0.000853	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD4—leprosy	1.14e-05	0.000824	CbGpPWpGaD
Sirolimus—MTOR—Disease—CD4—leprosy	1.06e-05	0.00076	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL2—leprosy	1.05e-05	0.000758	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SDHD—leprosy	9.84e-06	0.000708	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL2—leprosy	9.17e-06	0.00066	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL2—leprosy	6.8e-06	0.00049	CbGpPWpGaD
